Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with β-cyclodextrin and hydroxypropyl-β-cyclodextrin

Ranpise, Nisharani S.; Kulkarni, Nilesh S.; Mair, Parth D.; Ranade, Arati N.

doi:10.3109/10837450903002165

Cited by 26 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10,11] Ranpise et al and Sunita et al investigated the inclusion of aceclofenac in hydroxypropyl-b-CD. [12,13] The possibility to increase the complexing ability of b-CD by their prior coprecipitation with molecules like choline dichloride able to increase the aqueous solubility of lipophilic drugs seemed to represent a further approach to the utilization of b-CD as aqueous solubility and therefore attempt has been made to prepare inclusion complexes of aceclofenac with coprecipitated b-cyclodextrin (b-CD) with an aim to improve its extent and rate of dissolution.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of Dissolution Behavior of Aceclofenac by Complexation with β-Cyclodextrin-Choline Dichloride Coprecipitate

Dua

Pabreja

Ramana

2011

Journal of Dispersion Science and Technology

View full text Add to dashboard Cite

The objective of the present investigation was to study the effect of presence of choline dichloride (CDC) in b-cyclodextrin (b-CD) on in vitro dissolution of aceclofenac (AF) from molecular inclusion complexes. The molecular inclusion complexes of AF with b-CD coprecipitated with CDC in 1:1 and 1:2 M ratio were prepared using kneading method. In vitro dissolution of pure drug, physical mixtures, and cyclodextrin inclusion complexes (AF-b-CD-CDC) were carried out. Molecular inclusion complexes of aceclofenac with coprecipitated b-CD showed considerable increase in the dissolution rate in comparison with physical mixture and pure drug in 0.1 N HCl, pH 1.2 and phosphate buffer, pH, 7.4. Inclusion complexes with 1:2 M ratio showed maximum dissolution rate in comparison to other ratios. FTIR spectroscopy and differential scanning calorimetry studies indicated no interaction between AF and b-CD-CDC in complexes in solid state. Dissolution enhancement was attributed to the formation of water soluble inclusion complexes with the precipitated form of b-CD. The in vitro release from all the formulations was best described by first order kinetics (R 2 ¼ 0.9354 and 0.9268 in 0.1 N HCl and phosphate buffer, respectively) followed by Higuchi release model (R 2 ¼ 0.9029 and 0.9578 in 0.1 N HCl and phosphate buffer, respectively). In conclusion, dissolution of aceclofenac can be enhanced by using the b-CD-CDC coprecipitate as a host molecule.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhancement of Dissolution Behavior of Aceclofenac by Complexation with β-Cyclodextrin-Choline Dichloride Coprecipitate

Dua

Pabreja

Ramana

2011

Journal of Dispersion Science and Technology

View full text Add to dashboard Cite

show abstract

“…Ranpise et al, 2010 [30] Aceclofenac/β-CD/HP-β-CD Developed formulations based on inclusion complexes of aceclofenac with β-CD and HP-β-CD and evaluated their anti-inflammatory and analgesic effects (in vivo).…”

Section: Samal Et Al 2012 [29]mentioning

confidence: 99%

Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of medicines in the treatment of inflammation, fever, and pain. However, evidence has demonstrated that these drugs can induce significant toxicity. In the search for innovative strategies to overcome NSAID-related problems, the incorporation of drugs into cyclodextrins (CDs) has demonstrated promising results. This study aims to review the impact of cyclodextrin incorporation on the biopharmaceutical and pharmacological properties of non-steroidal anti-inflammatory drugs. A systematic search for papers published between 2010 and 2020 was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and the following search terms: “Complexation”; AND “Cyclodextrin”; AND “non-steroidal anti-inflammatory drug”. A total of 24 different NSAIDs, 12 types of CDs, and 60 distinct inclusion complexes were identified, with meloxicam and β-CD appearing in most studies. The results of the present review suggest that CDs are drug delivery systems capable of improving the pharmacological and biopharmaceutical properties of non-steroidal anti-inflammatory drugs.

show abstract

“…Based on the sugar molecules in the ring structure, cyclodextrins are categorized in three main classes: α–cyclodextrins, β–cyclodextrins, and γ–cyclodextrins containing 6-, 7-, and 8-membered sugar rings in the cyclic structure. 121 The drug molecules are enclosed within cage-like ring structure. Primary advantage of these structures is delivery of the drug compounds without changing their molecular structure.…”

Section: Nanotechnology Approach In Medicinementioning

confidence: 99%

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Kwon¹,

Kim²,

Khang³

et al. 2020

IJN

View full text Add to dashboard Cite

Glaucoma is a group of diseases characterized by progressive degeneration of retinal ganglion cells, leading to irreversible blindness. Currently, intraocular pressure reduction is the only established treatment available for glaucoma. With this treatment, the progression of the disease can only be delayed and there is no recovery. In addition, the commercially available eye drops have the disadvantage of low compliance and short therapeutic time, while glaucoma surgery always has the risk of failure due to wound fibrosis. Nanotechnology can overcome the limitations of the current treatment through the encapsulation and conjugation of drugs used for lowering intraocular pressure and antifibrotic agents using biodegradable or biocompatible nanoparticles for the sustained release of the drugs to protect the damaged ocular cells. Furthermore, using nanotechnology, treatment can be administered in various forms, including eye drops, contact lens, and ocular inserts, according to the convenience of the patients. Despite the promising results of delaying the progression of glaucoma, the regeneration of damaged ocular cells, including trabecular meshwork and retinal ganglion cells, is another critical hurdle to overcome. Bone marrow-derived mesenchymal stem cells and Müller glia cells can secrete neurogenic factors that trigger the regeneration of associated cells, including trabecular meshwork and retinal ganglion cells. In conclusion, this review highlights the potential therapeutic applications of nanotechnology- and stem cell-based methods that can be employed for the protection and regeneration of ocular cells.

show abstract

Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with β-cyclodextrin and hydroxypropyl-β-cyclodextrin

Cited by 26 publications

References 5 publications

Enhancement of Dissolution Behavior of Aceclofenac by Complexation with β-Cyclodextrin-Choline Dichloride Coprecipitate

Enhancement of Dissolution Behavior of Aceclofenac by Complexation with β-Cyclodextrin-Choline Dichloride Coprecipitate

Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Contact Info

Product

Resources

About